VivoSeq
Other

Lymphoproliferative Disease

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Lymphoproliferative Disease is an early-stage landscape with 0 programs across 2 companies. The most active players are AstraZeneca, WiSP Wissenschaftlicher Service Pharma GmbH.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

60/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalW

WiSP Wissenschaftlicher Service Pharma GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Terminated3 · 21%
Recruiting1 · 7%
Not yet recruiting1 · 7%
Withdrawn1 · 7%
Active, not recruiting1 · 7%
Other1 · 7%

Clinical Trials

Trial Activity

14 trials

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Recruiting·PPierre Fabre Medicament·Phase 3·NCT03394365·115 enrolled
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Active, not recruiting·UUniversity College, London·Phase 1·NCT03131934·18 enrolled
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
Not yet recruiting·WWest China Hospital·Phase 1·NCT06666153·27 enrolled
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Completed·Children's Oncology Group·Phase 2·NCT00066469·55 enrolled
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Completed·GGeron Corporation·Phase 1·NCT00124189·48 enrolled
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Completed·AA.O. Ospedale Papa Giovanni XXIII·Phase 4·NCT01088724·4 enrolled
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Completed·DDiako Ev. Diakonie-Krankenhaus gemeinnützige GmbH·Phase 2·NCT02042391·60 enrolled
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy
Completed·WWiSP Wissenschaftlicher Service Pharma GmbH·Phase 2/3·NCT01085058·169 enrolled
Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Completed·UUniversity of Edinburgh·Phase 3·NCT00033475·50 enrolled
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Terminated·UUniversity of Washington·Phase 2·NCT03498612·9 enrolled
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Terminated·AstraZeneca logoAstraZeneca·Phase 1·NCT00123942·31 enrolled
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 1·NCT00176475·2 enrolled
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
Withdrawn·UUniversity of Alabama at Birmingham·Phase 1·NCT00002956
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Unknown status·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT04504526·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)